Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Ratio: 2010-2025

Historic Equity Ratio for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to 0.25.

  • Lineage Cell Therapeutics' Equity Ratio fell 63.35% to 0.25 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.25, marking a year-over-year decrease of 63.35%. This contributed to the annual value of 0.69 for FY2024, which is 10.28% up from last year.
  • Lineage Cell Therapeutics' Equity Ratio amounted to 0.25 in Q3 2025, which was down 53.86% from 0.53 recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Equity Ratio registered a high of 0.93 during Q2 2021, and its lowest value of 0.25 during Q3 2025.
  • Over the past 3 years, Lineage Cell Therapeutics' median Equity Ratio value was 0.64 (recorded in 2023), while the average stood at 0.61.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Equity Ratio rose by 12.25% in 2022, and later plummeted by 63.35% in 2025.
  • Lineage Cell Therapeutics' Equity Ratio (Quarterly) stood at 0.53 in 2021, then grew by 12.25% to 0.59 in 2022, then climbed by 5.86% to 0.63 in 2023, then climbed by 10.28% to 0.69 in 2024, then plummeted by 63.35% to 0.25 in 2025.
  • Its Equity Ratio stands at 0.25 for Q3 2025, versus 0.53 for Q2 2025 and 0.71 for Q1 2025.